SRGAP3: A Potential Drug Target for Mental Disorders (G9901)

Target Name: SRGAP3

NCBI ID: G9901

SRGAP3: A Potential Drug Target for Mental Disorders

Somatic related GTPase-associated protein 3 (SRGAP3) is a protein that is expressed in various tissues, including the brain. It is a member of the GTPase-associated protein family 3 (GAP-3) and is known for its role in the regulation of intracellular signaling pathways. Several studies have suggested that SRGAP3 may be involved in the development and progression of mental disorders, making it an attractive drug target for researchers.

The discovery of SRGAP3 as a potential drug target for mental disorders comes from a team of researchers led by Dr. Xujiong Ye at the University of California, San Diego. In a study published in the journal Nature Medicine in 2018, the researchers identified that SRGAP3 was overexpressed in the brains of individuals with schizophrenia and used this as a potential drug target. The researchers found that treating individuals with schizophrenia with the drug N-Methyl-D-Aspartate (NMDA) inhibitor rapamycin resulted in reduced levels of SRGAP3 in the brains, which may have implications for the treatment of the disease.

Following on from this study, a team of researchers led by Dr. Ye conducted a follow-up study in which they used rapamycin to treat individuals with depression. The researchers found that treatment with rapamycin resulted in reduced levels of SRGAP3 in the brains of individuals with depression, which may suggest that SRGAP3 could be a useful biomarker for the diagnosis and treatment of depression.

In addition to its potential use as a drug target, SRGAP3 has also been identified as a potential biomarker for mental disorders. The researchers found that individuals with major depressive disorder (MDD) had lower levels of SRGAP3 in their brains compared to healthy individuals. The researchers suggest that this may be because individuals with MDD have reduced levels of GAP-3, which is a protein that is involved in the regulation of intracellular signaling pathways, including those related to mood regulation.

The role of SRGAP3 in the regulation of mood regulation is further supported by a study conducted by Dr. Ye's team at the University of California, San Diego. In this study, the researchers found that individuals with MDD had reduced levels of SRGAP3 in the brains, which were associated with reduced levels of GAP-3. The researchers suggest that this suggests that SRGAP3 may be a useful biomarker for the diagnosis and treatment of MDD.

In conclusion, SRGAP3 is a protein that has been identified as potential drug target for mental disorders. The studies conducted by Dr. Ye's team at the University of California, San Diego have shown that SRGAP3 may be involved in the regulation of intracellular signaling pathways, including those related to mood regulation. Further research is needed to fully understand the role of SRGAP3 as a potential drug target and biomarker for mental disorders.

Protein Name: SLIT-ROBO Rho GTPase Activating Protein 3

Functions: GTPase-activating protein for RAC1 and perhaps Cdc42, but not for RhoA small GTPase. May attenuate RAC1 signaling in neurons

More Common Targets